Molecular pathogenesis of intrahepatic cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences - Tập 22 Số 2 - Trang 101-113 - 2015
Jesper B. Andersen1
1Andersen Group Biotech Research and Innovation Centre University of Copenhagen Ole Maaløes Vej 5 DK‐2200 Copenhagen N Denmark

Tóm tắt

AbstractCholangiocarcinoma (CCA) is an orphan cancer of the hepatobiliary tract, the incidence of which has increased in the past decade. The molecular pathogenesis of this treatment‐refractory disease is poorly understood. Desmoplasia is a key causal feature of CCA; however, a majority of tumors develop with no apparent etiological background. The impact of the stromal compartment on tumor progression as well as resistance to therapy is in vogue, and the epithelial‐stromal crosstalk may present a target for novel treatment strategies. As such, the complexity of tumor cellularity and the molecular mechanisms underlying the diversity of growth patterns of this malignancy remain a clinical concern. It is crucial to advance our present understanding of the molecular pathogenesis of CCA to improve current clinical strategies and patient outcome. This will facilitate the delineation of patient subsets and individualization for precision therapies. Many questions persevere as to the evolutionary process and cellular origin of the initial transforming event, the context of intratumoral plasticity and the causal driver action. Next‐generation sequencing has begun to underline the persistent alterations, which may be the trigger of acquired drug resistance, and the cause of metastasis and disease recurrence. A complex issue that remains is to account for the heterogeneous pool of “backseat” aberrations, which in chromosomal proximity to the causative variant are likely to influence, for example, drug response. This review explores the recent advances in defining the molecular pathways implicated in the development of this devastating disease and, which present putative clinical strategies.

Từ khóa


Tài liệu tham khảo

10.1016/j.jhep.2014.01.021

Bragazzi CM, 2012, Cholangiocarcinoma: epidemiology and risk factors, Transl Gastrointest Cancer, 1, 21

10.3109/00365521.2011.589472

10.1136/gutjnl-2011-301748

10.1053/j.gastro.2009.02.038

Andersen JB, 2014, A perspective on molecular therapy in cholangiocarcinoma: present status and future directions, Future Med (Hepatic Oncology), 1, 143

10.1056/NEJMoa0908721

10.1186/2045-3701-1-5

10.1016/j.cgh.2012.09.009

10.1016/j.jhep.2012.02.022

10.1007/s10552-013-0167-3

10.1136/oemed-2012-101246

10.1001/jamasurg.2013.5137

10.1126/science.959840

10.1200/JCO.2011.38.2994

10.1038/nature09460

10.1056/NEJMoa1113205

10.1126/science.1227670

10.4251/wjgo.v4.i5.94

10.1038/sj.onc.1209558

10.1172/JCI63212

10.1053/j.gastro.2013.03.013

10.1172/JCI63065

10.1158/0008-5472.CAN-13-1911

10.1016/j.ccr.2013.04.019

10.1002/hep.26165

10.1016/j.ajpath.2013.12.002

10.1158/0008-5472.CAN-11-3596

10.1073/pnas.1311707110

10.1172/JCI27282

10.1097/MOG.0b013e3283523c7e

10.1053/j.gastro.2013.02.018

10.1038/onc.2012.617

10.1053/j.gastro.2011.12.005

10.1002/hep.25890

10.1053/j.gastro.2013.01.001

10.1038/onc.2012.315

10.1111/j.1477-2574.2010.00286.x

10.1158/1078-0432.CCR-07-1473

10.1002/hep.25570

10.1016/j.jhep.2004.04.030

10.1053/hupa.2000.9782

10.1016/S1386-6346(01)00100-0

10.3748/wjg.14.7033

10.1053/jhep.2002.34435

10.1055/s-2002-34507

10.1038/modpathol.3800204

10.1136/gut.52.5.706

10.1002/gcc.20540

10.1016/j.biopha.2010.06.009

10.1038/ng.2806

10.1136/gut.48.3.403

10.2307/3580128

10.1111/j.1478-3231.2005.01106.x

10.1634/theoncologist.2011-0386

10.1016/j.humpath.2011.12.007

10.1002/1096-9896(2000)9999:9999<::AID-PATH816>3.0.CO;2-K

Tokumoto N, 2005, Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas, Int J Oncol, 27, 973

10.1038/ng.2273

10.1038/ng.2813

10.1053/j.gastro.2014.01.062

10.1038/ng.2256

10.1371/journal.pone.0026168

10.1073/pnas.1111963108

10.1634/theoncologist.2013-0352

10.1158/2159-8290.CD-13-0050

10.1002/hep.26890

10.1371/journal.pgen.1004135

10.1016/j.humpath.2014.03.014

10.1016/S0168-9525(99)01971-X

10.1038/5947

Isomoto H, 2009, Epigenetic alterations associated with cholangiocarcinoma (review), Oncol Rep, 22, 227

10.1111/j.1478-3231.2007.01624.x

10.5858/2007-131-923-MPOMCI

10.1016/S0002-9440(10)64262-9

10.1002/path.1139

10.1038/modpathol.3800287

10.1053/j.gastro.2006.10.037

10.1016/S0168-8278(02)00269-6

10.1126/scitranslmed.3001338

10.1101/gad.947102

10.1016/j.ccr.2004.06.023

Pinto A, 1993, 5‐Aza‐2′‐deoxycytidine (Decitabine) and 5‐azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends, Leukemia, 7, 151

10.1038/bjc.2011.102

10.1158/1940-6207.CAPR-13-0104

10.1002/hep.26721

10.1038/nature10866

10.4291/wjgp.v1.i2.23

10.1006/jsre.1999.5615

10.1002/hep.20966

10.1053/j.gastro.2005.03.010

10.1158/0008-5472.CAN-06-2130

10.1186/1756-8722-3-37

10.1053/j.gastro.2012.04.007

10.1038/onc.2009.211

10.1038/nature03702

10.1002/hep.23381

10.1053/j.gastro.2006.02.057

10.1038/sj.onc.1210648

10.1038/sj.onc.1210436

10.3748/wjg.13.6465

10.1272/jnms.76.188

10.1016/j.jhep.2008.09.015

10.1002/hep.22838

10.1016/j.amjsurg.2004.01.007

10.1159/000354531

10.1111/j.1742-4658.2012.08618.x

10.1002/hep.26577

10.1097/00000478-199908000-00006

10.1158/2159-8290.CD-12-0348

10.1634/theoncologist.2009-0010

Thrum S, 2011, Polo‐like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma, Anticancer Res, 31, 3289

10.1002/hep.26484

10.1038/nature01972

10.1126/science.1171362

Chuaysri C, 2009, Alpha‐smooth muscle actin‐positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma, Oncol Rep, 21, 957

10.1152/ajpgi.00292.2009

10.1002/hep.24588

10.1111/j.1478-3231.2011.02687.x

10.1242/dev.02529

10.1002/hep.26511

10.1136/gut.2008.148619

10.1053/j.gastro.2005.01.055

10.1371/journal.pone.0046512

10.1111/j.1872-034X.2012.01111.x

10.1016/j.jhep.2005.10.030

10.1111/j.1572-0241.2007.01403.x

10.1074/jbc.M602201200

10.3748/wjg.v9.i6.1302

Wu T, 2004, The cyclooxygenase‐2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells, Mol Cancer Ther, 3, 299, 10.1158/1535-7163.299.3.3

10.1016/j.ccr.2009.10.015

10.1038/leu.2010.289

10.1016/j.tcb.2012.04.006

10.1073/pnas.0912203107

10.1016/j.ccr.2009.09.026

10.1038/sj.bjc.6606011

10.3390/cells1040886

Thông tin
Thông tin xuất bản

Journal of Hepato-Biliary-Pancreatic Sciences

Tập 22 Số 2

101-113

Thông tin tác giả